EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical and Molecular Evolution During Panitumumab-Containing Therapy in EGFR-Amplified Esophagogastric Adenocarcinoma

Devyn T Coskey, Kruti B Vora, Yin Guo, Ryan H Moy

The Oncologist · 04.11.2026

DOI: 10.1093/oncolo/oyag440 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 04.11.2026. Verfasst von Devyn T Coskey und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY, USA. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Esophagogastric adenocarcinoma (EGA) is an aggressive malignancy with limited targeted treatment options. EGFR amplification defines a molecular subset associated with response to EGFR-directed therapy, although mechanisms of resistance remain poorly characterized. We present a 66-year-old man with EGFR-amplified metastatic EGA who achieved a metabolic response on positron emission tomography-CT (PET/CT) during panitumumab-containing therapy, accompanied by loss of detectable EGFR amplification on serial plasma circulating tumor DNA (ctDNA). At progression, repeat tissue biopsy demonstrated HER2 IHC 2+/SISH-positive disease not identified at baseline, and next-generation sequencing identified ERBB2 and KRAS amplifications. These findings suggest ERBB2-mediated bypass signaling as a potential mechanism of resistance to EGFR inhibition, with concurrent KRAS amplification as a possible contributor. It also demonstrates the utility of longitudinal tissue and plasma profiling to capture tumor evolution, identify potential resistance mechanisms, and inform adaptive treatment strategies.

Schlagwörter

Stichwörter der Autor:innen

EGFR amplificationERBB2Esophagogastric adenocarcinomaHER2KRASctDNA

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY, USA.
  • Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA.
  • Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.

Zitieren

APA

Coskey, D. T., Vora, K. B., Guo, Y., & Moy, R. H. (2026). Clinical and Molecular Evolution During Panitumumab-Containing Therapy in EGFR-Amplified Esophagogastric Adenocarcinoma. The Oncologist. https://doi.org/10.1093/oncolo/oyag440

Vancouver

Coskey DT, Vora KB, Guo Y, Moy RH. Clinical and Molecular Evolution During Panitumumab-Containing Therapy in EGFR-Amplified Esophagogastric Adenocarcinoma. The Oncologist. 2026. doi:10.1093/oncolo/oyag440

BibTeX
@article{Coskey2026,
  author = {Coskey, Devyn T and Vora, Kruti B and Guo, Yin and Moy, Ryan H},
  title = {Clinical and Molecular Evolution During Panitumumab-Containing Therapy in EGFR-Amplified Esophagogastric Adenocarcinoma},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag440}
}
Kostenlos starten →